Skip to main
DOCS

Doximity (DOCS) Stock Forecast & Price Target

Doximity (DOCS) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 22%
Buy 44%
Hold 22%
Sell 6%
Strong Sell 6%

Bulls say

Doximity Inc. has experienced significant growth, with its point-of-care (POC) and formulary offerings expanding by more than 100% during the recent buying season, indicating strong demand for its services among U.S. medical professionals. Following a positive shift in market sentiment, the company’s shares have risen by 3.2% since September 8, reflecting investor confidence in its forthcoming performance. Furthermore, the second-quarter guidance appears not only achievable but also potentially optimistic, aided by greater visibility from increased upfront buying related to its expanded offerings.

Bears say

The current economic uncertainty has prompted downward guidance revisions for Doximity's pharmaceutical clients, negatively impacting expectations for FY'23 and FY'24. Additionally, Doximity's stock appears expensive when compared to its software peers, raising concerns about potential volatility if the company fails to meet elevated investor expectations. The anticipated scrutiny on financial performance further complicates the outlook, as any failure to deliver positive results or raise guidance could lead to significant disappointment among investors.

Doximity (DOCS) has been analyzed by 18 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 44% recommend Buy, 22% suggest Holding, 6% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Doximity (DOCS) Forecast

Analysts have given Doximity (DOCS) a Buy based on their latest research and market trends.

According to 18 analysts, Doximity (DOCS) has a Buy consensus rating as of Jan 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $67.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $67.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Doximity (DOCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.